Greenlight biosciences

GreenLight Biosciences, founded in 2008, joined the Unicorn Club in June 2020 after raising a $102 million Series D led by Morningside. Headquartered in Lexington, Massachusetts, United States, the biotech unicorn has raised $225 million across six funding rounds. The company develops RNA-based products for vaccines, antibody therapies, pandemic preparedness, crop protection, and pollinator health. Investors include Morningside, Cormorant Asset Management, and Tao Capital Partners. Funding supports platform expansion, commercial scaling, and RNA-based innovation across human, animal, and agricultural health sectors.